Global Information
회사소개 | 문의 | 비교리스트

만성신장질환(만성신부전) : 파이프라인 리뷰

Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020

리서치사 Global Markets Direct
발행일 2020년 04월 상품 코드 232792
페이지 정보 영문 276 Pages
가격
US $ 2,000 ₩ 2,396,000 PDF by E-mail (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,792,000 PDF by E-mail (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,189,000 PDF by E-mail (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


만성신장질환(만성신부전) : 파이프라인 리뷰 Chronic Kidney Disease (Chronic Renal Failure) - Pipeline Review, H1 2020
발행일 : 2020년 04월 페이지 정보 : 영문 276 Pages

만성 신부전이란 신장 기능이 서서히 감퇴하는 질환이며, 징후 및 증상에는 오심, 구토, 식욕 감퇴, 피로감, 근력 저하, 수면 장애, 딸꾹질, 다리 및 발목 붓기 등이 있습니다. 연령, 당뇨병, 고혈압, 심장질환, 흡연, 비만, 고콜레스테롤 등이 질병 소인입니다.

세계의 만성신장질환(만성신부전)(Chronic Kidney Disease (Chronic Renal Failure)) 치료제 파이프라인에 대해 조사 분석했으며, 현재의 개발 파이프라인 상황과 최신 동향, 치료제 개요, 주요 기업 및 개발중인 제품 리뷰 등의 정보를 전해드립니다.

목차

서론

  • 분석 범위

만성신장질환(만성신부전) 개요

치료제 개발

  • 만성신장질환(만성신부전)용 파이프라인 제품 : 개요
  • 만성신장질환(만성신부전)용 파이프라인 제품 : 비교 분석

만성신장질환(만성신부전) : 개발중인 치료제 - 기업별

만성신장질환(만성신부전) : 조사중인 치료제 - 대학 및 연구기관별

만성신장질환(만성신부전) : 파이프라인 제품 개요

  • 후기 단계 제품
  • 임상 단계 제품
  • 초기 단계 제품
  • 개발 단계가 불명인 제품

만성신장질환(만성신부전) : 개발중인 제품 - 기업별

만성신장질환(만성신부전) : 조사중인 제품 - 대학 및 연구기관별

만성신장질환(만성신부전) : 치료제 개발에 참여하고 있는 기업

  • Acceleron Pharma, Inc.
  • Angion Biomedica Corp.
  • Astellas Pharma Inc.
  • Bayer AG
  • Bio-inRen
  • BioAegis Therapeutics, Inc.
  • Boryung Pharmaceutical Co., Ltd.
  • Complexa, Inc.
  • Evotec AG
  • F. Hoffmann-La Roche Ltd.
  • Gilead Sciences, Inc.
  • Intercept Pharmaceuticals, Inc.
  • Ionis Pharmaceuticals, Inc.
  • Lupin Limited
  • Nippon Zoki Pharmaceutical Co., Ltd.
  • OPKO Health, Inc.
  • Otsuka Holdings Co., Ltd.
  • Prismic Pharmaceuticals, Inc.
  • Prolong Pharmaceuticals, LLC
  • ProMetic Life Sciences Inc.
  • Reata Pharmaceuticals, Inc.
  • Red Glead Discovery AB
  • RegenMedTX, LLC
  • Resverlogix Corp.
  • Sphaera Pharma Pvt. Ltd.
  • Stelic Institute & Co., Inc.
  • Thrasos Therapeutics Inc.
  • Toray Industries, Inc.
  • VBS Pharmaceuticals
  • Vicore Pharma AB

만성신장질환(만성신부전) : 치료제 평가

  • 단독치료 제품(Monotherapy Products)별
  • 병용 제품(Combination Products)별
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 종류별

치료제 개요

  • (palmidrol + silibinin)
  • ambrisentan
  • ANG-3070
  • ANG-3281
  • ANG-3586
  • ANG-4011
  • apabetalone
  • AS-2444697
  • ASP-6858
  • bardoxolone methyl
  • BR-05001
  • BRN-1889
  • C-21
  • calcium succinate
  • CAR Peptide
  • cardiotoxin
  • Cell Therapy for Chronic Kidney Disease and Type-2 diabetes
  • CXA-10
  • Drug for Kidney Diseases
  • Drugs to Inhibit CYP24 for Secondary Hyperparathyroidism, Chronic Kidney Disease and Oncology
  • finerenone
  • INT-767
  • IONIS-FXIRx
  • KBP-5074
  • NZ-419
  • obinutuzumab
  • PBI-4050
  • PBI-4419
  • Protein to Activate BMP-7 for Kidney Diseases, Metabolic Disorders and Osteoarthritis
  • Recombinant Plasma Gelsolin Replacement for Renal Disease
  • rivaroxaban
  • Sanguinate
  • 기타

최신 파이프라인 동향

휴지중인 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

  • 주목 뉴스와 프레스 릴리스

부록

도표

KSM 16.05.31

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

List of Tables

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algernon Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Algomedix Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Allena Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Angion Biomedica Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by apceth Biopharma GmbH, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Arch Biopartners Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Aronora Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by AstraZeneca Plc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Bayer AG, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by BioAegis Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boehringer Ingelheim International GmbH, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Boryung Pharmaceutical Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cadila Healthcare Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cellmid Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Cinkate Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Corvidia Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Daiichi Sankyo Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DiaMedica Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dimerix Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Dizal (Jiangsu) Pharmaceutical Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DJS Antibodies Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by DURECT Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Evotec SE, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by G3 Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by GNI Group Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Icagen Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Indalo Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by INVENT Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ITB-Med AB, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kaleido Biosciences Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KBP BioSciences Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by KidneyCure Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Kintai Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Klotho Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Liminal BioSciences Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Merck & Co Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Meridigen Biotech Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Novartis AG, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OPKO Health Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Opsidio LLC, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by OrthoTrophix Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by ProKidney LLC, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reata Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Redx Pharma Plc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Reliance Life Sciences Pvt Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Renibus Therapeutics Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Resverlogix Corp, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sarfez Pharmaceuticals Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Scohia Pharma Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sentien Biotechnologies Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Sphaera Pharma Pte Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unicocell Biomed Co Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Unity Biotechnology Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vascular BioSciences, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by VESSL Therapeutics Ltd, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Pipeline by Vidasym Inc, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects, H1 2020 (Contd..2), H1 2020
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products, H1 2020

List of Figures

  • Number of Products under Development for Chronic Kidney Disease (Chronic Renal Failure), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides an overview of the Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline landscape.

Chronic kidney disease is the slow loss of kidney function over time. Signs and symptoms of kidney disease include nausea, vomiting, loss of appetite, fatigue and weakness, sleep problems, hiccups and swelling of feet and ankles. The predisposing factors include age, diabetes, high blood pressure, heart disease, smoking, obesity and high cholesterol.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Kidney Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Chronic Kidney Disease (Chronic Renal Failure) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 4, 11, 11, 2, 23, 14 and 2 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 3 molecules, respectively.

Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
  • The pipeline guide reviews pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Chronic Kidney Disease (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Chronic Kidney Disease (Genito Urinary System And Sex Hormones)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Chronic Kidney Disease (Genito Urinary System And Sex Hormones).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Chronic Kidney Disease (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Chronic Kidney Disease (Chronic Renal Failure) - Overview
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Development
  • Chronic Kidney Disease (Chronic Renal Failure) - Therapeutics Assessment
  • Chronic Kidney Disease (Chronic Renal Failure) - Companies Involved in Therapeutics Development
  • Chronic Kidney Disease (Chronic Renal Failure) - Drug Profiles
  • Chronic Kidney Disease (Chronic Renal Failure) - Dormant Projects
  • Chronic Kidney Disease (Chronic Renal Failure) - Discontinued Products
  • Chronic Kidney Disease (Chronic Renal Failure) - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q